CREO vs. MXCT, EKF, IUG, NCYT, POLX, IHC, AVO, RUA, SUN, and MHC
Should you be buying Creo Medical Group stock or one of its competitors? The main competitors of Creo Medical Group include MaxCyte (MXCT), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.
Creo Medical Group vs. Its Competitors
Creo Medical Group (LON:CREO) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
56.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 22.4% of Creo Medical Group shares are held by company insiders. Comparatively, 1.5% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, MaxCyte had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Creo Medical Group. MaxCyte's average media sentiment score of 0.28 beat Creo Medical Group's score of 0.00 indicating that MaxCyte is being referred to more favorably in the news media.
MaxCyte received 47 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 68.92% of users gave MaxCyte an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.
Creo Medical Group has a net margin of -73.93% compared to MaxCyte's net margin of -78.37%. MaxCyte's return on equity of -16.01% beat Creo Medical Group's return on equity.
Creo Medical Group has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.
Creo Medical Group has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Summary
MaxCyte beats Creo Medical Group on 10 of the 15 factors compared between the two stocks.
Get Creo Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creo Medical Group Competitors List
Related Companies and Tools
This page (LON:CREO) was last updated on 6/13/2025 by MarketBeat.com Staff
